Safety of Four COVID-19 Vaccines across Primary Doses 1, 2, 3 and Booster: A Prospective Cohort Study of Australian Community Pharmacy Vaccinations

Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax) and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine adverse events following immunisation (AEFI) at days 3 and 42 after primary doses 1,...

Descripción completa

Detalles Bibliográficos
Autores principales: Salter, Sandra M., Li, Dani, Trentino, Kevin, Nissen, Lisa, Lee, Kenneth, Orlemann, Karin, Peters, Ian, Murray, Kevin, Leeb, Alan, Deng, Lucy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786585/
https://www.ncbi.nlm.nih.gov/pubmed/36560426
http://dx.doi.org/10.3390/vaccines10122017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786585/
https://www.ncbi.nlm.nih.gov/pubmed/36560426
http://dx.doi.org/10.3390/vaccines10122017

Ejemplares similares